Mounjaro update

From single use vials, to explaining off-label prescribing and educating patients on administration, PDL has some advice on Mounjaro In recent weeks, the PDL Professional Officers have received a number of queries regarding pharmacists’ obligations and liability when dispensing Mounjaro® (tirzepatide). Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ODT funding leaves patients without care
Next The best of Blooms